Benzinga's Top #PreMarket Gainers - bluebird bio (NASDAQ:BLUE)

Idera Pharmaceuticals IncIDRA

gained 6.44 percent to $3.80 in pre-market trading. JP Morgan initiated coverage on Idera Pharmaceuticals with a Overweight rating.

Plasmatech Biopharmaceuticals IncPTBI

shares rose 5.05 percent to $7.70 in pre-market trading following the announcement of license deal for gene therapy in Fanconi anemia, CRISPR/Cas9-Based technology platform.

bluebird bio IncBLUE

shares rose 4.98 percent to $189.82 in pre-market trading after the company reported new data from HGB-205 study. Philip Gregory, D. Phil., joined bluebird bio as Chief Scientific Officer. JP Morgan maintained bluebird bio with a Overweight and raised the price target from $200.00 to $244.00.

Trivascular Technologies Inc TRIV

shares climbed 3.91 percent to $7.18 in pre-market trading after the company reported the FDA approval of Ovation iX(TM) Iliac Stent Graft.

Standard Pacific Corp. SPF

shares climbed 1.80 percent to $8.50 in pre-market trading. Standard Pacific and

Ryland Group IncRYL

agreed to merge in an all-stock transaction.

Market News and Data brought to you by Benzinga APIs